Placental sFLT1 is associated with complement activation and syncytiotrophoblast damage in preeclampsia
The immune complement system protects against pathogens; however, excess activation results in disease like hemolytic uremic syndrome, a clinical imitator of preeclampsia. Vascular endothelial factor (VEGF) protects against aberrant complement activation and is inhibited by soluble fms-like tyrosine...
Saved in:
Main Authors: | Ai-ris Yonekura Collier (Author), Zsuzsanna Zsengeller (Author), Elizabeth Pernicone (Author), Saira Salahuddin (Author), Eliyahu V. Khankin (Author), S. Ananth Karumanchi (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2019-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chemical optimization of siRNA for safe and efficient silencing of placental sFLT1
by: Sarah M. Davis, et al.
Published: (2022) -
Increased placental sFlt-1 but unchanged PlGF expression in late-onset preeclampsia
by: Laura Ehrlich, et al.
Published: (2017) -
Soyghurt Potentially Controls the Level of sFlt1 and PLGF in Preeclampsia Maternal Serum-Induced Placental Trophoblast Cell in vitro
by: Khairani AF, et al.
Published: (2024) -
Use of serum and urinary soluble sFlt-1 and PLGF in the diagnosis of preeclampsia
by: Ping Tang, et al.
Published: (2017) -
Placental expression of sFlt-1 and PlGF in early preeclampsia vs. early IUGR vs. age-matched healthy pregnancies
by: Alice Hoeller, et al.
Published: (2017)